human OA cartilage; healthy cartilage tissues; plasma; synovium tissues; mouse cartilage; mouse joint
PHCs; hBMSCs; SW1353; HEK293; HEK-293T
other disease animal model; genetically engineered animal model
inflammation (inhibits); apoptosis (inhibits); proliferation (promotes); mRNA stability (inhibits); other pathway/process (inhibits)
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; circRNA-seq; Microarray; Actinomycin D / DRB Stability Assay; RT-qPCR; RNA-seq; FISH / smFISH; Clinical Sample Validation; RIP (RNA Immunoprecipitation); RNA Pull-Down; Luciferase Reporter Assay; Transfection; CCK8; EdU Staining; Colony Formation Assay; Annexin V/PI Flow Cytometry; IHC (Immunohistochemistry); IF (Immunofluorescence); ELISA; Western Blot; In Vivo Animal Model; Bioinformatics Analysis
circIRAK3 expression in plasma increased with higher OARSI scores and may serve as a diagnostic biomarker, indicator of OA progression, and therapeutic target for OA.
circIRAK3 is up-regulated in OA cartilage and plasma and acts as a compensatory anti-inflammatory regulator. It binds HNRNP U, reduces HNRNP U-mediated stabilization of IL-1beta, TNF-alpha, and IL-6 mRNAs, and thereby promotes proinflammatory cytokine mRNA degradation. Functionally, circIRAK3 protects chondrocytes, supports hBMSC chondrogenesis, delays DMM-induced cartilage degeneration, and may serve as an OA biomarker and therapeutic target.
0.8834
CircIRAK3 exerts negative feedback regulation on inflammation by binding to HNRNP U and destabilizing proinflammatory cytokine mRNA in osteoarthritis and chondrogenesis.
combined biological and clinical study